ETERNAL PROJECT

New collaborative project to boost reduction of the environmental impact of pharmaceutical products through their entire life cycle

New collaborative project to boost reduction of the environmental impact of pharmaceutical products through their entire life cycle
October 21, 2022

The ETERNAL project has successfully kicked-off in Valencia, Spain. This new four-year EC Horizon Europe Research and Innovation Action will contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only active pharmaceutical ingredients and residues or metabolites, but other chemicals and by-products of the production process. In other words, safe and sustainable pharmaceutical lifecycles by design.

Asphalion experts André Mota and Oriol Penon attended the meeting. Asphalion will provide regulatory guidance to support understanding of the environmental exposure and ecotoxicity during pharmaceuticals development to ensure the solutions are commercially deployable in the future through a compliant by design approach according to applicable regulatory guidelines and technical standards. Due to Asphalion expertise in the regulatory field, Asphalion will also engage with policy makers, regulators and standards bodies to ensure a regulatory framework that enables green innovation.

You can read the complete press release here: ETERNAL PROJECT PRESS RELEASE

For further information:

ETERNAL INFORMATION

This project has received funding from the European Union’s Horizon Europe Framework Programme (HORIZON) under grant agreement No 101057668.

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting